The new standard in precision retinal diagnostics.
At Enlighten Imaging, we are pioneers in the field of retinal hyperspectral imaging, revolutionizing the way we detect and diagnose eye, brain and systemic diseases.
We are a start-up company developing a platform technology that will leverage hyperspectral retinal imaging and a cloud-based AI data analysis service to provide qualitative and quantitative insights into ocular health.
Our Vision
To deliver the new standard in precision retinal diagnostics for eye, brain and systemic diseases.
Leverage the power of hyperspectral retinal imaging and big data analytics for precision diagnostic and prognostic biomarker services at scale.
Our Mission
What is Retinal Hyperspectral Imaging?
Retinal hyperspectral imaging is a groundbreaking technique that captures images of the retina across a wide range of wavelengths. By analyzing the spectral signatures of retinal tissues, this technology provides comprehensive information about cellular composition, metabolic activity, and microvascular patterns.
What is hypercolour?
The hypercolour is a non-mydriatic hyperspectral fundus camera developed by Enlighten Imaging over the past four years. It captures a series of high-resolution retinal images at wavelengths ranging from 450nm to 850nm, with a 45-degree field-of-view, in just one-third of a second, semi-autonomously.
Our Team
Prof. Peter van Wijngaarden
Founder & CMO
Dr. Xavier Hadoux
Founder & CEO
Dr. Francis Labrecque
CTO
Mr. Maxime Jannaud
Head of Software Development
Ms. Darvy Dang
Head of Clinical Operations
Our Board
Peter Larsen
Managing Director Optometry Warehouse Former President, Topcon Medical Systems Ex-Group Eye Health Strategy Director, Specsavers
Keith Martin
Managing Director, CERA
Professor of Ophthalmology, University of Melbourne
Founder of Quethera
Darren Kelly
Founder & CEO of Fibrotech, Certa Therapeutics
Executive Chair, OccuRx
Ex-Associate Dean of Innovation & Enterprise, University of Melbourne